Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837984 | 0.87 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30837935 | 0.87 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30837988 | 0.87 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30837885 | 0.86 | TLR2 (0.34) | TLR2PPARGP2RY12 | |
| SCHEMBL30842639 | 0.84 | TLR2 (0.37) | TLR2PPARG | |
| SCHEMBL30977775 | 0.84 | KLK7 (0.33) | CHRM2CHRM4CHRM1CHRM3PPARG | |
| SCHEMBL30977747 | 0.83 | KLK7 (0.32) | PPARG | |
| SCHEMBL30977700 | 0.83 | KLK7 (0.32) | TLR2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL31035892 | 0.83 | TLR2 (0.36) | TLR2PPARG | |
| SCHEMBL30977718 | 0.83 | CHRM2 (0.32) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102347-A1 | Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NANOVATION THERAPEUTICS INC. (CA) | 2026-04-16 | — | — | US | disclosed |
| EP-4594298-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| CN-120051455-A | Sulfur-containing ionizable lipids for delivery of therapeutic agents | 内诺维什疗法股份有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2024065042-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102347-A1 | Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NSUN2, SGMS2, SGMS1 | TLR2 1475/4885SLC2A1 34/4885CHRM2 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.